News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
Subscribe To Our Newsletter & Stay Updated
